MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.diabres.2025.112954

Медицинская библиотека · Diabetes research and clinical practice · 2025

Efficacy and safety of different once-weekly glucagon-like peptide-1 receptor agonists-A systematic review and Bayesian network meta-analysis.

Xu Ying, Ji Guikai, Shi Chenyang, Tan Yijiong, Wang Li, Gui Yaxing

СтатьяNetwork Meta-AnalysisСистематический обзорПеревод в очереди

Аннотация

BACKGROUND

There are less comparisons among once-weekly glucagon-like peptide-1 receptor agonists (GLP-1RAs),which is not conducive to refined clinical treatment.

METHODS

We searched in Pubmed, Embase, and Cochrane Central Register of Controlled Trials from database creation date to June 1, 2024. The primary glycemic efficacy was changes from baseline to endpoint for HbA1c. We performed Bayesian network meta-analysis calculating mean differences (MDs) for continuous outcomes and odds ratios (OR) for dichotomous outcomes.

RESULTS

All once-weekly GLP-1RAs outperformed placebo in reducing HbA1c (MD: -0.66 % [-0.81 %, -0.5 %] for dulaglutide 1.5 mg to -1.4 % [-1.6 %, -1.2 %] for tirzepatide 15 mg). Tirzepatide 15 mg showed superior weight loss (MD: -8.7 [-10, -6.8]) and systolic blood pressure reduction (MD: -4.8 [-8.2, -1.4]) versus other GLP-1RAs, but higher nausea (OR: 6.4 [4.3, 9.6]) and diarrhea risks (OR: 3.5 [2.5, 5.2]). Polyethylene glycol loxenatide 100 μg provided effective glucose control with the lowest gastrointestinal and discontinuation risks.

CONCLUSIONS

Tirzepatide demonstrates superior efficacy in glycemic control, weight reduction, and blood pressure reduction, yet is associated with high risk of adverse events. In contrast, polyethylene glycol loxenatide offers effective glycemic management with the lowest withdrawal probability. For patients with Type 2 diabetes mellitus and cardiovascular disease, dulaglutide is preferable.

Для цитирования: Xu Ying, Ji Guikai, Shi Chenyang, Tan Yijiong, Wang Li, Gui Yaxing. Efficacy and safety of different once-weekly glucagon-like peptide-1 receptor agonists-A systematic review and Bayesian network meta-analysis.. Diabetes research and clinical practice. 2025. DOI: 10.1016/j.diabres.2025.112954.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.